Integrating genomics to dig deeper into Wilms tumour biology by Mifsud, W & Pritchard-Jones, K
  
Integrating genomics to dig deeper into Wilms tumour biology  
 
William Mifsud and Kathy Pritchard-Jones 
 
Refers to Gadd, S. et al. A Children's Oncology Group and TARGET initiative exploring the 
genetic landscape of Wilms tumor. Nat. Genet. http://dx.doi.org/10.1038/ng.3940 (2017). 
 
A new study provides a comprehensive catalogue of the genetic changes in Wilms tumour. 
Understanding the interplay between genetic and epigenetic aberrations during tumorigenesis and 
clonal evolution is fundamental to enabling prediction of who is at risk and which tumours will 
relapse when so many are curable. 
 
 
Wilms tumour is the commonest paediatric renal malignancy. Improvements in chemotherapy, 
surgery, and radiotherapy, which is used in a minority of patients,now result in a 90% cure rate. 
However, predicting and treating tumour relapse remains difficult and a considerable number of 
patients might be overtreated or undertreated. Furthermore, even when cured of the original tumour, 
many patients have to contend with adverse treatment effects, including cardiac dysfunction, 
hepatotoxicity, secondary malignancies, and pregnancy complications, potentially compounded by 
their genetic susceptibility to renal failure, heart disease, and other tumours.  
 
Over the past few decades, numerous studies aimed to elucidate the genetic events leading to Wilms 
tumour development. Discoveries have been tremendously accelerated by the application of 
massively parallel sequencing to large collections of Wilms tumour specimens from collaborative 
national and international studies. Three papers published in 2014 and 2015 expanded the repertoire 
of known Wilms tumour cancer genes from five to twelve3-5. In the most comprehensive genomic 
characterisation of Wilms tumours to date, Gadd et al.6 analysed a discovery set of 117 tumours (78 
with favourable histology that relapsed and a large set of 39 high-risk, diffuse anaplastic tumours) 
using whole-genome sequencing in 80 tumours and whole-exome sequencing in 37 tumours, as 
well as mRNAseq and miRNAseq. In addition, the team tested a panel of 37 genes identified in the 
discovery set  in 651 additional tumours by targeted capture sequencing: only around two-thirds of 
samples in this validation set had deleterious mutations in ≥1 of these 37 genes, whereas genome-
wide sequencing of the discovery set found deleterious mutations in 115 of 117 (nearly all) 
tumours. Nevertheless, the results of this study expand the list of Wilms tumour cancer genes to ≥30 
genes. The challenge is that none of these genes individually accounts for tumour development 
in >5% of patients.  
 
The authors make an admirable attempt to reduce this complexity by mapping the discovered genes 
to a simplified set of developmental and molecular pathways. A number of genes identified that are 
recurrently mutated in Wilms tumour are specifically important in early nephrogenesis, whereas 
other genes have wide-ranging functions that include roles in nephrogenesis. Specifically, by 
performing parallel studies of mRNA and miRNA gene expression and methylation profiles, Gadd 
et al.6 find correlations with mutated genes that indicate different Wilms tumour subgroups. One 
group has features of a preserved nephrogenic state and another group predominantly has 
mutational and gene expression profiles indicating aberrant induction of the metanephric 
mesenchyme that normally triggers a mesenchymal–epithelial transition. 
 
A subset of the tumours with a preserved nephrogenic state have mutations in the miRNA 
processing machinery, which are associated with overall reductions in miRNA levels, especially 
those of let-7a, which induces differentiation. By contrast, another group of tumours with a 
preserved nephrogenic state has similar miRNA expression profiles but no mutations in miRNA 
processing genes. The authors suggest that this discrepancy might be caused by copy number gain 
  
in LIN28B (which downregulates let-7a maturation) and/or loss of LET-7A. However, these copy 
number aberrations are not focal and, indeed, LIN28B copy number gain is a consequence of gain 
of the entire chromosome 6 in all cases. Hence, expression of miRNA processing genes might be 
affected directly by copy number changes.  
 
In the tumours with aberrant induction, the researchers reviewed the known functions of the 
mutated genes and their regulatory interactions.  They plausibly surmise that the aberrant induction 
is mediated by Wnt–β-catenin signalling (as expected from previous findings) and associated 
dysregulation of histone acetylation and transcriptional elongation, specifically through WNT9 and 
WNT4. 
 
Notably, the clustering used to delineate the developmental and molecular pathways is not observed 
in tumours with diffuse anaplasia, which typically have mutations in TP53 and consequent genomic 
instability. This finding highlights a remaining challenge in the molecular characterisation of 
paediatric tumours in general. Tumours with considerable genomic instability, especially secondary 
to TP53 aberrations, have a predictable high risk of relapse; however, many relapsing tumours do 
not have TP53 mutations and seem to not have the same degree of genomic instability. Within the 
non-anaplastic clusters of Wilms tumour, detecting any molecular signature of relapse is 
particularly difficult. We suggest that genomic instability might be more difficult to detect when a 
tumour is sampled at a time when the clone with genomic instability has not yet taken over the 
entire tumour. Copy number changes and rearrangements are difficult to detect when they are 
subclonal in a tumour sample; indeed, controlling for sampling bias might be difficult, as all 
analyses depend on one small sample (at most a few ml) from a large tumour mass (typically 
several hundred ml). Alternatively, one can argue that the occurrence of tumours containing low 
levels of clones or only regional clones with considerable genomic instability is improbable, as 
these clones would rapidly outproliferate the rest of the tumour. We think that this argument might 
not apply in the context of a developmental tumour. In this setting, even the tumour precursor cells 
(nephrogenic rest cells) are typically proliferating rapidly at the time of tumorigenesis and, in a 
tumour characterised by proliferation and failure of differentiation of rapidly dividing progenitor 
cells, the growth advantage of cells with an unstable genome might be comparably small. Solving 
this problem will require analysis of multiple samples per tumour and improved methods of 
detecting subclonal structural genomic changes, such as genomic copy number changes, copy-
neutral loss of heterozygosity, and genomic rearrangements.  
 
The study by Gadd et al.6 also confirms that many Wilms tumours have multiple tumorigenic 
genomic alterations. This finding and previous evidence of clonal evolution at copy number level7  
set the foundation for future work that examines the temporal and spatial relationships and 
evolutionary trajectories of genomic events and tumour subclones, and whether and how these 
respond to treatment. 
 
In Wilms tumour specifically, 37% of tumours have epimutations at the imprinted 11p15 locus, and 
an additional 32% have paternal uniparental disomy (pUPD) at the same locus, both resulting in 
IGF2 overexpression and H19 expression loss8. pUPD is a very early, if not the earliest, event in 
those tumours harbouring it. pUPD was found in precursor nephrogenic rests9 and in all sampled 
parts of each tumour harbouring the change in a Wilms tumour multisampling study7. The 11p15 
epimutation is possibly also a very early event. Studying the temporal and evolutionary relationship 
between this epigenetic event and the genetic mutations that might precede or follow it would be 
interesting. 
 
Finally, this study confirms, much more comprehensively than before, a relatively high rate of 
germline mutations (10%) that most probably predispose to Wilms tumour formation. Together 
with the previous finding that constitutional 11p15 abnormalities are present in 3% of  patients with 
  
Wilms tumour10 and that mosaic postzygotic mutations might be difficult to detect, the real 
proportion of tumours that arise owing to an inherited mutation or an acquired mosaic mutation is 
likely to be higher. Future studies that systematically investigate this issue are required, for instance 
by comparing a patient’s nontumorous cells with those of their parents. Improved understanding of 
this area should clarify the earliest events in Wilms tumour development and should also let us 
identify those patients at risk of subsequent malignancies or who have a raised risk of family 
members developing paediatric cancer. Studying the interplay of germline or mosaic predisposing 
mutations and epimutations at 11p15 and potentially other genomic loci might also be fascinating. 
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Wilms tumour formation”.   
  
 
 
 
 
1 Dome, J. S. et al. Children's Oncology Group's 2013 blueprint for research: renal tumors. 
Pediatr Blood Cancer 60, 994-1000, doi:10.1002/pbc.24419 (2013). 
2 Brok, J., Treger, T. D., Gooskens, S. L., van den Heuvel-Eibrink, M. M. & Pritchard-Jones, 
K. Biology and treatment of renal tumours in childhood. Eur J Cancer 68, 179-195, 
doi:10.1016/j.ejca.2016.09.005 (2016). 
3 Torrezan, G. T. et al. Recurrent somatic mutation in DROSHA induces microRNA profile 
changes in Wilms tumour. Nat Commun 5, 4039, doi:10.1038/ncomms5039 (2014). 
4 Walz, A. L. et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in 
favorable histology Wilms tumors. Cancer Cell 27, 286-297, 
doi:10.1016/j.ccell.2015.01.003 (2015). 
5 Wegert, J. et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA 
microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, 
298-311, doi:10.1016/j.ccell.2015.01.002 (2015). 
6 Gadd, S. et al. A Children's Oncology Group and TARGET initiative exploring the genetic 
landscape of Wilms tumor. Nat Genet, doi:10.1038/ng.3940 (2017). 
7 Cresswell, G. D. et al. Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal 
Evolution and Clinical Implications. EBioMedicine 9, 120-129, 
doi:10.1016/j.ebiom.2016.05.029 (2016). 
8 Scott, R. H. et al. Stratification of Wilms tumor by genetic and epigenetic analysis. 
Oncotarget 3, 327-335, doi:10.18632/oncotarget.468 (2012). 
9 Charles, A. K., Brown, K. W. & Berry, P. J. Microdissecting the genetic events in 
nephrogenic rests and Wilms' tumor development. Am J Pathol 153, 991-1000, 
doi:10.1016/S0002-9440(10)65641-6 (1998). 
10 Scott, R. H. et al. Constitutional 11p15 abnormalities, including heritable imprinting center 
mutations, cause nonsyndromic Wilms tumor. Nat Genet 40, 1329-1334, 
doi:10.1038/ng.243 (2008). 
 
